SI-BONE reports Q1 revenue $37.9M (+16% YoY); raises FY2024 guidance to $164-166M

SI-BONE, Inc.

2024-Q1 EPS reported -$0.27 revenue$37,867,000

Worldwide revenue $37.9M, up 16% YoY; U.S. revenue $35.4M, also up 16%.
Gross margin ~79%, down from ~82% due to product and procedure mix.
Net loss $10.9M ($0.27 diluted EPS) vs $11.1M ($0.32) in Q1 2023; adjusted EBITDA loss $4.0M.
FY2024 revenue guidance raised to $164-166M (18-20% growth) from $162-165M.
Surpassed 100,000 procedures; introduced smaller diameter iFuse Bedrock Granite implant.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

SI-BONE, Inc. reported the quarter ended March 31, 2024 results: revenue $37.9 million, net income $10.9 million, or $0.27 per diluted share. Guidance raised.

Period: the quarter ended March 31, 2024
Revenue: $37.9 million
Net income: $10.9 million, or $0.27 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (all comparisons are to the prior year period) • Worldwide revenue of $37.9 million, representing growth of ~16% • U.S. revenue of $35.4 million, representing growth of ~16% • Gross margin of ~79% • Over 1,100 U.S. active physicians, representing an increase of

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

SI-BONE, Inc. filing history →

Source: SEC EDGAR

accession 0001459839-24-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.